all report title image
  • Published On : Dec 2022
  • Code : CMI5419
  • Industry : Medical Devices
  • Pages : 162
  • Formats :

The global drug delivery device market was valued at US$ 258,800.0 Mn in 2021 and is forecast to reach the value of US$ 423,431.7 Mn by 2028 at a CAGR of 7.4% between 2022 and 2028. The drug delivery device market is experiencing strong growth due to the increasing burden of chronic/non-communicable diseases and increasing adoption of technologically advanced drug delivery devices worldwide. Moreover, growth in the biologics market and growing geriatric population across the world is expected to boost the growth of the market. However, factors such as product recalls and risk of needlestick injuries are expected to hamper growth of the market.

Global Drug Delivery Device Market: Regional Insights

Based on geography, the global drug delivery device market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period due to the increasing burden of chronic diseases, rise in demand for drug delivery devices, and increase in awareness regarding the advantages of such devices in the region. For instance, in March 2022, Corium announced that the U.S. Food and Drug Administration (FDA) has approved ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer's type. ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin.

Europe and Asia Pacific are also expected to witness significant growth in the global drug delivery device market due to the rise in prevalence of non-communicable diseases and rise in demand for drug delivery devices in these regions. For instance, according to the World Health Organization (WHO/Europe), non-communicable diseases (NCDs) are the leading cause of mortality across the European Region. NCDs, such as cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases, account for nearly 75% of deaths across the region. Thus, the demand for drug delivery devices is increasing rapidly in Europe and Asia Pacific.

Figure 1. Global Drug Delivery Device Market Share (%), by Region, 2022

Drug Delivery Device  | Coherent Market Insights

Global Drug Delivery Device Market Drivers:

Increasing burden of chronic/non-communicable diseases worldwide is expected to drive growth of the global drug delivery device market over the forecast period. For instance, implantable drug delivery devices offer unique patient solutions for chronic diseases. According to the World Health Organization (WHO), non-communicable diseases (NCDs), such as heart disease, stroke, diabetes, cancer, and chronic lung disease, are responsible for 74% of all deaths worldwide. More than three-quarters of all NCD deaths occur in low- and middle-income countries. This in turn is expected to aid in the growth of the global drug delivery device market.

Increasing adoption of technologically advanced drug delivery devices for effective drug delivery is expected to boost the growth of the global drug delivery device market over the forecast period. For instance, in June 2022, Gufic Biosciences launched new drug delivery system (NDDS), named dual-chamber bags (DCB) at an affordable price in India. These bags are two-chamber IV bags made up of polypropylene (DEHP free) with a peel-able aluminium foil allowing the storage of unstable drugs which need a reconstitution just before the administration to the patient. This in turn is expected to propel the growth of the market.

Global Drug Delivery Device Market Opportunities:

Rapid growth in the biologics market is expected to provide significant growth opportunities for players in the drug delivery device market. For instance, drug delivery device/system are expected to improve targeted delivery of biologics. Thus, market players are focusing on developing novel drug delivery devices/systems. Moreover, research to develop drug delivery systems for biologics is expected to increase over the forecast period, driving the growth of the market. Novartis invested US$ 700 million in its biologic's facility in Singapore, and Bristol-Myers Squibb invested nearly US$ 900 million in an Irish large-scale biologics facility.

Growing geriatric population around the world is expected to offer lucrative growth opportunities for players in the global drug delivery device market. For instance, the ageing population tends to have a higher prevalence of chronic diseases worldwide, as geriatric population is more prone to chronic/non-communicable diseases than the younger population. According to WHO, by 2030, 1 in 6 people in the world will be aged 60 years or over, and the world’s population of people aged 60 years and older will double (2.1 billion) by 2050. This in turn is expected to increase demand for drug delivery devices across the world.

CMI table icon

Drug Delivery Device Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 258,800.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 7.4% 2028 Value Projection: US$ 423,431.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Route of Administration: Injectable, Topical, Ocular, and Other Routes of Administration
  • By Application: Cancer, Cardiovascular, Diabetes, Infectious Diseases, and Other Applications
  • By End User: Hospitals, Ambulatory Surgical Centers, and Other End Users
Companies covered:

Pfizer Inc., Novartis AG (Sandoz), F. Hoffmann-La Roche Ltd., Johnson & Johnson, and Bayer AG, among others.

Growth Drivers:
  • Increasing burden of chronic/non-communicable diseases
  • Increasing adoption of technologically advanced drug delivery devices 
Restraints & Challenges:
  • Product recalls
  • Risk of needlestick injuries

Global Drug Delivery Device Market Trends:

The major trend driving the drug delivery device market growth is the increasing implementation of strategic initiatives and development of novel products. For instance, in December 2020, Agile Therapeutics Inc. announced the launch of a new non-invasive contraceptive patch, named Twirla (levonorgestrel and Ethinyl estradiol) transdermal system. The development of such products is fueling the use of drug delivery products, driving the market growth.​

Moreover, with the increasing prevalence of chronic diseases, the development of biologics is also increasing at a rapid pace across the world. Players in the market are focusing on developing and launching technically-advanced drug delivery devices for effective delivery of biologics. Due to their large molecular size and fragile molecular structure, biologic medicines are delivered through parenteral drug delivery system. This trend is also expected to continue during the forecast period, driving the growth of the global drug delivery device market.

Global Drug Delivery Device Market Restraints:

Product recalls are expected to hamper the growth of the global drug delivery device market. For instance, in December 2019, U.S. FDA recalled Medtronic’s SynchroMed II systems after deaths were reported in patients implanted with the SynchroMed II system. FDA categorized a voluntary recall of certain SynchroMed II implantable drug infusion pumps as a Class I event

Risk of needlestick injuries is expected to hinder growth of the global drug delivery device market. For instance, drug delivery devices available in the market are mainly injectable devices that use needles to inject therapeutics into the body. Needlestick injuries are known to occur frequently in healthcare settings and can be serious. These injuries are one of the most important occupational hazards among healthcare workers worldwide.

Figure 2. Global Drug Delivery Device Market Share (%), by Route of Administration, 2022

Drug Delivery Device  | Coherent Market Insights

Global Drug Delivery Device Market Segmentation:

The drug delivery device market report is segmented into Route of Administration, Application, End User, and Geography.

Based on Route of Administration, the market is segmented into Injectable, Topical, Ocular, and Other Routes of Administration. Of which, Injectable Segment is expected to dominate the drug delivery device market during the forecast period and this is attributed to the increase in use of injectables to treat chronic/non-communicable diseases. Injectable route is the most effective route of administration, as the bioavailability of the drug is higher than other routes.

Topical Segment is also expected to witness significant growth in the near future and this is owing to the increase in prevalence of diabetes. Transdermal drug administration refers to substances that are absorbed through the skin.

Based on Application, the market is segmented into Cancer, Cardiovascular, Diabetes, Infectious Diseases, and Other Applications. Out of which, Cancer Segment is expected to dominate the market over the forecast period and this is attributed to the increase in burden of cancer.

Segment is also expected to witness significant growth in the near future and this is owing to the increase in prevalence of cardiovascular diseases worldwide.

Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, and Other End Users. Out of which, Hospitals Segment is expected to dominate the market over the forecast period and this is attributed to the increase in use of drug delivery devices in hospitals.

Ambulatory Surgical Centers Segment is also expected to witness significant growth in the near future and this is owing to the increase in adoption of injectables drugs across these centers.

Global Drug Delivery Device Market: Key Developments

In March 2022, Pfizer Inc. acquired Arena Pharmaceuticals to expand its portfolio of therapeutic candidates in gastroenterology, dermatology, and others.

In August 2021, Bayer AG Acquired 100% shares of the biopharmaceutical company Vividion Therapeutics, to expand its product portfolio in novel drug discovery technologies.

In April 2021, Roche and Biocorp entered a partnership to launch Mallya, an innovative medical device to better the daily life of diabetes patients.

Global Drug Delivery Device Market: Key Companies Insights

The global drug delivery device market is highly competitive. This is attributed to the increasing demand for drug delivery devices around the world, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global drug delivery device market are Pfizer Inc., Novartis AG (Sandoz), F. Hoffmann-La Roche Ltd., Johnson & Johnson, and Bayer AG, among others.

*Definition: A drug delivery device is defined as a device or formulation that enables a therapeutic substance to reach its site of action without reaching the non-target cells, organs, and/or tissues. Drug delivery devices are used as part of one or more medical treatments.  

A drug delivery device is defined as the device used to deliver a therapeutic substance and enables a therapeutic substance to reach its site of action without reaching non-target cells, organs, and/or tissues. These devices are used as part of one or more medical treatments to delivery a drug or a therapeutic agent via a specific route of administration.

Market Dynamics:

Increasing burden of chronic/non-communicable diseases, increasing adoption of technologically advanced drug delivery devices, rapid growth in the biologics market, and the outbreak of COVID-19 are major factors expected to drive growth of the global drug delivery device market.

For instance, in September 2022, Corium, Inc. announced that ADLARITY (donepezil transdermal system) is now available for prescription in the United States for the treatment of people with mild, moderate, or severe dementia of Alzheimer's type. Moreover, in February 2022, Takeda received the U.S. Food and Drug Administration (USFDA) approval for TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe, which is used to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Key features of the study:

  • This report provides in-depth analysis of the global drug delivery device market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global drug delivery device market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., Novartis AG (Sandoz), F. Hoffmann-La Roche Ltd., Johnson & Johnson, and Bayer AG, among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global drug delivery device market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug delivery device market.

Detailed Segmentation:

  • Global Drug Delivery Device Market, By Route of Administration:
    • Injectable
    • Topical
    • Ocular
    • Other Routes of Administration
  • Global Drug Delivery Device Market, By Application:
    • Cancer
    • Cardiovascular
    • Diabetes
    • Infectious Diseases
    • Other Applications
  • Global Drug Delivery Device Market, By End User:
    • Hospitals
    • Ambulatory Surgical Centers
    • Other End Users
  • Global Drug Delivery Device Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Pfizer Inc.
    • Novartis AG (Sandoz)
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson
    • Bayer AG

Frequently Asked Questions

The global drug delivery device market size is estimated to be valued at US$ 276,611.0 Million in 2022 and is expected to exhibit a CAGR of 7.4% between 2022 and 2028.
Increasing burden of chronic/non-communicable diseases and rise in adoption of technologically advanced drug delivery devices is fueling the market.
The others segment is the leading route of administration segment in the market.
Product recalls and risk of needlestick injuries are major factors restraining market.
Major players operating in the market are Pfizer Inc., Novartis AG (Sandoz), F. Hoffmann-La Roche Ltd., Johnson & Johnson, and Bayer AG, among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo